-
ALSO READ
Coronavirus vaccine update: 20 mn Americans may get vaccine by December-end
Coronavirus vaccine update: Chinese-backed hackers targeted Moderna
Coronavirus vaccine update: Russia may partner India for producing vaccines
Coronavirus vaccine update: Chinese vaccine shows promise in animal tests
Coronavirus vaccine update: Bharat Biotech starts human trial at PGI-Rohtak
-
Coronavirus vaccine update: In a year since the coronavirus pandemic hit the world, it has left over 1.3 million people dead and affected over 55 million across the globe. But some positive developments lately around a possible vaccine for the virus has raised some hopes. US-based Moderna has joined Pfizer in approaching the vaccine finish line, with the company saying its vaccine candidate is 94.5 per cent effective in preventing infection. For its part, Pfizer has announced last week that its vaccine candidate was over 90 per cent effective. The two companies plan to apply for emergency-use authorisation later this month, and they could begin to immunise 20 million people as early as December. Meanwhile, Russia has claimed that its Sputnik V coronavirus vaccine is 92 per cent effective. And, India's 'Covaxin', Oxford-Astrazeneca, and Johnson & Johnson's vaccine have all shown promising results at different stages of trials. What does a coronavirus vaccine's effectiveness mean? It refers to the likelihood that a coronavirus shot will work for people. Coronavirus vaccine progress 1. China coronavirus vaccine update Sinovac Biotech’s experimental Covid-19 vaccine CoronaVac triggered a quick immune response but the level of antibodies produced was lower than in people who had recovered from the disease, preliminary trial results showed on Wednesday. While the early to mid-stage trials were not designed to assess the efficacy of CoronaVac, researchers said it could provide sufficient protection, based on their experience with other vaccines and data from preclinical studies with macaques. 2. Moderna vaccine update Moderna’s investigational vaccine candidate had proved to be 94.5 per cent effective in preventing Covid-19 infection based on interim data from a large-scale late-stage trial, the company said on Monday. This makes Moderna the second US firm to report late-stage efficacy data from vaccine trials -- the other one being Pfizer. ALSO READ: Moderna's Covid vaccine 94.5% effective, edges over Pfizer on storage 3. Pfizer vaccine update Pfizer’s vaccine, developed in collaboration with Germany’s BioNTech SE, has “an extraordinarily high degree of efficacy, more than 90 per cent, close to 95 per cent,” according to Anthony Fauci, the top US infectious diseases doctor. That could be a key factor in overcoming reluctance to take pandemic vaccines that have been developed at top speed. The US might begin offering the vaccine to priority groups at the end of December, Fauci said. ALSO READ: Pfizer vaccine has 'extraordinarily high degree of efficacy': Fauci 4. Russia coronavirus vaccine in India: First batch of Sputnik V to reach Kanpur next week By next week, the first batch of Russia's Sputnik V vaccine for Covid-19 is likely to reach Kanpur's Ganesh Shankar Vidyarthi Medical College, where the vaccine's Phase-II and -III human clinical trials will be conducted.
The decision to conduct the human clinical trials of the vaccine was taken after Dr Reddy's Laboratories got approval from the Drugs Controller General of India (DCGI) in this regard, an official said.
5. Coronavirus vaccine India progress: Hyderabad's Biological E vaccine Biological E Limited (BE), a Hyderabad-based vaccine and pharmaceutical company, has initiated Phase-I, -II clinical trials of its Covid-19 subunit vaccine candidate in India following an approval from the DGCI. The announcement was made jointly by BE, Dynavax Technologies Corporation (Dynavax), a US-based vaccine focused biopharmaceutical company, and Baylor College of Medicine, a health sciences university in Houston, US. ALSO READ: Biological E's Covid-19 vaccine enters Phase I/II trial after DGCI nod 6. J&K coronavirus vaccine update: UK to run final stage trials of Janssen vaccine Britain will be the first country to run final-stage trials of an experimental coronavirus vaccine being developed by the pharmaceutical company Janssen, a subsidiary of Johnson & Johnson. Scientists have begun recruiting some 6,000 people across the UK for the 12-month trial. Dr Saul Faust, who is helping lead the study, said the research would start first in Britain but aims to recruit a total of 30,000 people in six countries around the world. 7. India in dialogue with Moderna, other biotech firms over progress in coronavirus vaccine development India is in a dialogue with the US-based biotech giant Moderna over the progress in the clinical trials of its coronavirus vaccine candidate, which the firm said had shown 94.5 per cent efficacy, according to news agency PTI. "We are in a dialogue not only with Moderna but also with Pfizer, Serum Institute,Bharat Biotech and Zydus Cadila over the progress of the clinical trials of each of the vaccine candidates and where their vaccines stand in terms of safety, immunogenicity and efficacy, and regulatory approvals," PTI quoted an official as saying. 8. Bharat Biotech coronavirus vaccine update Vaccine maker Bharat Biotech on Monday announced that it had commenced Phase-III trials of Covaxin, India's first indigenous vaccine for Covid-19. The Phase-III trials, which involve 26,000 volunteers across India, are being conducted in partnership with the Indian Council of Medical Research (ICMR). This is India's first Phase-III efficacy study for a Covid-19 vaccine, and the largest Phase-III efficacy trial ever conducted in India, the Hyderabad-based company said. 9. Iran coronavirus vaccine progress Iran Health Minister Saeed Namaki said on Monday that four Iranian companies had started human trials of a Covid-19 vaccine, media reported. The Iranian companies are among the global institutions currently in advanced stages of vaccine production, Namaki was quoted as saying. 10. Coronavirus vaccine cost: BioNTech to price vaccine below market rates BioNTech, the first in race to disclose interim data from a large-scale trial showing a highly effective Covid-19 vaccine, is planning to price its two-shot regimen below "typical market rates" and would differentiate pricing between countries or regions.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU